LeoPatrizi
- Inozyme Pharma (NASDAQ:INZY) traded higher on Tuesday after Jefferies assumed its coverage with a Buy rating and a $17 price target, citing three rare disease opportunities for the company’s lead asset, INZ-701.
- The enzyme replacement therapy is currently undergoing clinical studies for ENPP1 deficiency, calciphylaxis, and pseudoxanthoma elasticum (PXE), a trio of rare disorders caused by deficiencies of inorganic pyrophosphate (PPi), a regulator of cellular function.
- Jefferies analyst Maury Raycroft said INZ-701, designed to increase PPi, can achieve $2.5B in peak revenue. The experimental therapy can potentially increase PPi to normal levels in these disease areas, according to the analyst.
- Additionally, Raycroft underscored upcoming catalysts for INZ-701, including a Phase 1 readout in calciphylaxis and a topline readout from a pediatric pivotal trial for ENPP1 deficiency scheduled for Q4 and H2 2025, respectively.
